Peer-Reviewed Publication

Eur Heart J Qual Care Clin Outcomes2023;9(8):785-795.December 22, 2023Meta-Analysis

Renin-angiotensin system inhibition and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: findings from CCC-ACS project and a nationwide electronic health record-based cohort in China.

Zhi Li^1,2, Haonan Sun¹, Yongchen Hao³, Hangkuan Liu¹, Zhengyang Jin¹, Linjie Li¹, Chong Zhang¹, Min Ma⁴, Tianming Teng¹, Xiongwen Chen², Yujun Shen⁵, Ying Yu⁵, Jing Liu³, Arthur Mark Richards^6,7, Huay Cheem Tan^7,8, Dong Zhao³, Xin Zhou¹, Qing Yang¹

¹Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.

²Laboratory for Mechanisms and Therapies of Heart Diseases, School of Pharmacy, Tianjin Medical University, Tianjin, China.

³Departments of Epidemiology, the Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

⁴Clinical Data Processing Department, Beijing 1M Data Technology Corporation, Beijing, China.

⁵Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

⁶Cardiovascular Research Institute, National University Health System, Singapore.

⁷Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

⁸Department of Cardiology, National University Heart Centre, Singapore.

PubMed DOI

Abstract

AIMS: In acute coronary syndrome (ACS) patients without advanced renal dysfunction [estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2], early (within 24 h of admission) angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) is the guideline-directed medical therapy. The clinical efficacy of early ACEI/ARB therapy among ACS patients with advanced renal dysfunc…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

1m
affiliation

Other Funding

National Natural Science Foundation of China(82270349)
Tianjin Key Medical Discipline(TJYXZDXK-069C)
Tianjin Municipal Science and Technology Commission(19JCQNJC11500)
Tianjin Medical University(SYL001-303078100820)

MeSH Terms

Humans0Renin-Angiotensin System0Angiotensin-Converting Enzyme Inhibitors0Acute Coronary Syndrome*Angiotensin Receptor Antagonists0Hospital Mortality0Electronic Health Records0Kidney Diseases*

Keywords

ACEI/ARBAcute coronary syndromeAdvanced renal dysfunctionIn-hospital mortality

Article Info

PMID: 36731865
DOI: 10.1093/ehjqcco/qcad006
Received: January 19, 2023
Accepted: January 20, 2023

How to Cite

Li Z et al. Renin-angiotensin system inhibition and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: findings from CCC-ACS project and a nationwide electronic health record-based cohort in China. Eur Heart J Qual Care Clin Outcomes2023;9(8):785-795. doi:10.1093/ehjqcco/qcad006

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.